Cooperative mutagenesis driving pediatric pre-B cell leukemia
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Dr. Matthew Witkowski – University of Colorado Denver, AMC and DC
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Dr. Zhaohui Gu – Beckman Research Institute of the City of Hope, Duarte, CA
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Beckman Research Institute of the City of Hope, Duarte, CA
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Baylor College of Medicine, Houston, TX
Pediatric ALL CAR T-Cell Therapy
Pediatric ALL CAR T-Cell Therapy
Seattle Children’s Hospital, Seattle, WA